ARTICLE | Clinical News
FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic
September 21, 2018 4:26 PM UTC
Pharming Group N.V. (Euronext:PHARM) said FDA requested another clinical trial of Ruconest conestat alfa as a prophylactic for hereditary angioedema in a complete response letter for an sBLA in the indication.
Pharming, which fell €0.20 (20%) to €0.77 Sept. 19, declined to provide a timeline for a resubmission...
BCIQ Company Profiles
BCIQ Target Profiles